To outline upcoming FDA regulatory decisions for various therapies and products in September 2026.
Approach:
Oncology: TLX101-Px for glioma and zidesamtinib for ROS1-positive non-small cell lung cancer.
Neurology: UX111 for Sanfilippo syndrome type A, zilganersen for Alexander disease, and apitegromab for spinal muscular atrophy.
Rheumatology: Zilurgisertib for fibrodysplasia ossificans progressiva.
Dermatology: Aminolevulinic acid for superficial basal cell carcinoma.
Endocrinology: Tiratricol for monocarboxylate transporter 8 deficiency.
Cardiology: Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy.
Key Findings:
TLX101-Px received Orphan Drug and Fast Track designations.
Zidesamtinib has Breakthrough Therapy designation.
UX111's resubmission includes updated long-term clinical data.
Zilganersen demonstrated stabilization in gait speed in clinical trials.
Zilurgisertib reduced new heterotopic ossification lesions in patients.
Aminolevulinic acid's indication may expand to superficial basal cell carcinoma.
Tiratricol's application is based on multiple clinical trials.
Mavacamten met its primary endpoint in the SCOUT-HCM trial.
Interpretation:
The FDA is reviewing several significant applications across various therapeutic areas, with many products receiving designations that may expedite their approval process.
Limitations:
The outcomes of the FDA reviews are uncertain until official decisions are made.
The article does not provide detailed clinical trial results for all therapies.
Conclusion:
The upcoming PDUFA dates highlight a range of innovative therapies under review by the FDA.
